Hypofibrinogenemia
Hypofibrinogenemia Market

Hypofibrinogenemia is a rare disorder, which is characterized by a decrease in fibrinogen levels (<1.5 g/L), normal plasma fibrinogen levels that range from 1.5 g/L to 4.5 g/L. It is classified into two types, that is, Congenital Hypofibrinogenemia and Acquired Hypofibrinogenemia.


Fibrinogen is the main protein for clot formation that provides a matrix and mesh network required for clot strength. Maintaining fibrinogen levels is a vital therapeutic target in bleeding patients, especially in perioperative settings. Low fibrinogen levels are associated with decreased clot strength and are strongly associated with severe bleeding. 


Congenital fibrinogen disorders are caused due to genetic variants occurring within all three fibrinogen genes. But, each gene (FGA, FGB, FGG) differently displays specific variants, wherein “nonsense” variants are mostly found within FGA, while FGG variants are prevalently responsible for missense changes. 


In congenital Hypofibrinogenemia, genes responsible for producing fibrinogen (a critical blood clotting factor) cannot make a functional fibrinogen glycoprotein due to an inherited mutation. In contrast, acquired Hypofibrinogenemia can result from either severe hepatic disease or disseminated intravascular coagulation (DIC), cardiac surgery, etc. 


Hypofibrinogenemia Epidemiological Segmentation 

The Epidemiological Segmentation of Hypofibrinogenemia in 7MM from 2017 to 2030 is segmented as:- 

  • Total Cases 
  • Type-Specific Cases 
  • Acquired Hypofibrinogenemia cases


Hypofibrinogenemia Epidemiology 

  • The total prevalent population of Hypofibrinogenemia in 7MM in 2017 was 11,084  
  • The prevalent population of Hypofibrinogenemia in Spain in 2017 was 493


Hypofibrinogenemia Market

The market size of Hypofibrinogenemia in 7MM in 2017 was USD 161.5 Million.


Hypofibrinogenemia Emerging Drugs

The emerging drugs of the Hypofibrinogenemia market are 

  • BT524

And many others.  

 

Hypofibrinogenemia Marketed therapies

The Marketed therapies of the Hypofibrinogenemia market are 

  • RiaSTAP
  • Fibryna
  • FibCLOT (Clottafact)

And many others.  


Hypofibrinogenemia Key Players

The key players in the Hypofibrinogenemia market are

  • Biotest 
  • CSL Behring
  • Octapharma
  • LFB Biomedicaments

And many others.